Genomic Investigation of Unusual Responders (GENIUS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03740503 |
Recruitment Status :
Recruiting
First Posted : November 14, 2018
Last Update Posted : December 6, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Cancer Breast Cancer Non-small Cell Lung Cancer Colorectal Cancer Genitourinary Cancer Gynecological Cancer Upper Aerodigestive Tract Cancer Pancreatobiliary Gastrointestinal Cancer Melanoma (Skin) Rare Cancer Carcinoma of Unknown Primary |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Genomic Investigation of Unusual Responders |
Actual Study Start Date : | November 1, 2013 |
Estimated Primary Completion Date : | November 2024 |
Estimated Study Completion Date : | November 2024 |
- Genomic Characterization of Tumor Samples [ Time Frame: Through study completion, up to 2 years ]Characterization of the genetic changes that may explain a tumor's exceptional response or disaster to therapeutc agents.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.
- The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months
- Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)
- The patient must have sufficient archival tumor available for sequencing.
-
Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:
a)) Patients who have archival tissue stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.
b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program
Exclusion Criteria:
- None
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03740503
Contact: Celeste Yu | 416-946-4501 ext 5281 | celeste.yu@uhn.ca | |
Contact: Elizabeth Shah | 416-946-4501 ext 3833 | elizabeth.shah@uhn.ca |
Canada, Ontario | |
Princess Margaret Cancer Centre | Recruiting |
Toronto, Ontario, Canada, M5G 2M9 | |
Contact: Celeste Yu 416-946-4501 ext 5281 celeste.yu@uhn.ca | |
Contact: Elizabeth Shah 416-946-4501 ext 3833 elizabeth.shah@uhn.ca |
Principal Investigator: | David Cescon, MD | Princess Margaret Cancer Centre |
Responsible Party: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT03740503 |
Other Study ID Numbers: |
GENIUS |
First Posted: | November 14, 2018 Key Record Dates |
Last Update Posted: | December 6, 2023 |
Last Verified: | December 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cancer Breast Cancer Non- small Cell Lung Cancer Colorectal Cancer Genitourinary Cancer Gynecological Cancer |
Upper Aerodigestive Tract Cancer Pancreatobiliary Gastrointestinal Cancer Melanoma Cancer Rare Cancer Unknown Primary Cancer |
Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Melanoma Gastrointestinal Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Skin Diseases Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Intestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Female Urogenital Diseases |